GCG and type 2 diabetes mellitus: In obese or overweight individuals with type 2 diabetes, a GLP‐1/glucagon co‐agonist decreased hepatic fat content (Robertson et al., 2020), and in mice with diet‐induced MASH the co‐agonist reduced body weight and liver TG concentrations (Trevaskis et al., 2020).